New drug shows promise for Hard-to-Treat prostate cancer
NCT ID NCT03725761
First seen Jun 06, 2026 · Last updated Jun 13, 2026 · Updated 2 times
Summary
This study tests a drug called sacituzumab govitecan in men with advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease. About 31 participants will receive the drug, and researchers will measure PSA levels and progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.